Pomalidomide-amino-PEG3-NH2 hydrochloride is primarily used in the development of targeted cancer therapies. Its structure allows it to be conjugated with antibodies or other targeting molecules, enabling precise delivery to cancer cells. This compound is particularly valuable in the creation of antibody-drug conjugates (ADCs), where it helps enhance the therapeutic efficacy while minimizing off-target effects. Additionally, it is utilized in proteolysis-targeting chimeras (PROTACs) to degrade specific proteins involved in cancer progression. The PEG3 linker improves solubility and stability, making it a versatile tool in drug design and delivery systems.